Perhexiline during exercise training in coronary heart disease

Area of Science:

• Cardiology
• Exercise Physiology
• Pharmacology

Background:

• Exercise training is crucial for cardiac rehabilitation after myocardial infarction (MI) and coronary artery bypass grafting (CABG).
• Antianginal medications are often used in these patients, but their effect on exercise training response needs clarification.

Purpose of the Study:

• To investigate the impact of low-dose perhexiline on exercise training response in male patients post-MI or CABG.
• To assess if perhexiline affects exercise tolerance, left ventricular function, or hemodynamics during a structured exercise program.

Main Methods:

• A randomized, placebo-controlled trial involving 22 male patients (14 post-MI, 8 post-CABG).
• Subjects underwent 8 weeks of supervised, thrice-weekly exercise training.
• Evaluations included treadmill exercise testing and radionuclide ventriculography before and after the intervention.
• Blood perhexiline levels were monitored to ensure therapeutic steady-state.

Main Results:

• Both perhexiline and placebo groups showed improvements in exercise tolerance.
• No significant differences in exercise capacity or left ventricular ejection fraction were observed between groups.
• Resting blood pressure and left ventricular dimensions remained unchanged. No beta-adrenoceptor-blocking effects were detected.

Conclusions:

• Low-dose perhexiline, used as an antianginal therapy, does not impede the beneficial effects of exercise training in cardiac patients.
• Perhexiline is safe and does not negatively impact exercise performance or cardiac function in this population.
• This suggests concurrent use of perhexiline and exercise-based cardiac rehabilitation is feasible.